CD20

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity.

In humans CD20 is encoded by the MS4A1 gene.

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants that encode the same protein.

Function

The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane.

This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/CD20

Latest News for: cd20

Edit

Global Multiple Sclerosis Dynamic Market Forecast to 2026: Two Additional Anti-CD20 mAbs will Compete Against ...

MENA FN 04 Feb 2019

(MENAFN - GlobeNewsWire - Nasdaq) itemprop="articleBody"> Dublin, Feb. 04, 2019 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis. Dynamic Market Forecast to 2026" report has been added... ....

Edit

AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Previously Untreated Patients

Public Technologies 28 Jan 2019

'This latest IMBRUVICA FDA approval gives the healthcare community the first chemotherapy-free, anti-CD20 combination to treat CLL and SLL patients who have not yet started therapy ... In January 2017, IMBRUVICA was approved for adult patients with MZL who require systemic therapy and have received at least one prior anti-CD20-based therapy ... FDA ... cGVHD....

Edit

AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 ...

The Record 28 Jan 2019

"This latest IMBRUVICA FDA approval gives the healthcare community the first chemotherapy-free, anti-CD20 combination to treat CLL and SLL patients who have not yet started therapy ... The chemotherapy-free, anti-CD20 combination regimen also showed an 85 percent reduction in risk of ......

Edit

Judge Jeanine Pirro: Nancy Pelosi, you're a shutdown hypocrite -- Stop playing games and negotiate

Fox News 20 Jan 2019

Your buddies vacation with lobbyists in Puerto Rico during the shutdow, and you plan a jaunt to Europe while federal employees are trying to save every dollar ... ....

Edit

China Monoclonal Antibody Market Research Report, 2018-2025: Focus on Targets - PD-1,CD20,HER2,VEGF,EGFR, & TNF-a - ResearchAndMarkets.com

Pharmiweb 15 Jan 2019

China Monoclonal Antibody Market Research Report, 2018-2025. Focus on Targets - PD-1,CD20,HER2,VEGF,EGFR, & TNF-a - ResearchAndMark... Research and Markets ... ....

Edit

China Monoclonal Antibody (PD-1,CD20,HER2,VEGF,EGFR,TNF-a) Market, 2018-2025: Characteristics and Significance of Drugs Procurement with Target Quantity

Nasdaq Globe Newswire 15 Jan 2019

Dublin, Jan. 15, 2019 (GLOBE NEWSWIRE) -- The "China Monoclonal Antibody Market by Targets (PD-1,CD20,HER2,VEGF,EGFR,TNF-a) Research Report, 2018-2025" report has been added to ResearchAndMarkets.com's offering ... ....

Edit

China Monoclonal Antibody (PD-1,CD20,HER2,VEGF,EGFR,TNF-a) Market, 2018-2025: Market is Expected to Grow to RMB262.1 Billion in 2022 at a CAGR of 13.5% From 2017

PR Newswire 15 Jan 2019

The "China Monoclonal Antibody Market by Targets (PD-1,CD20,HER2,VEGF,EGFR,TNF-a) Research Report, 2018-2025" report has been added to ResearchAndMarkets.com's offering ... Second generation CD20- Ofatumumab & Ocrevus3.2.3 Third generation CD20- Obinutuzumab....

Edit

Clemson makes bid to be considered best team ever

Del Rio News-Herald 08 Jan 2019

SANTA CLARA, Calif. (AP) — There will never be a definitive answer to the greatest team in college football history. That didn't stop Clemson coach Dabo Swinney from lobbying for his squad ... 1 all season by The Associated Press. "There was a lot of talk about the best ever all year long," said Swinney, referring to Alabama ... But tonight, there's no doubt....

Edit

Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody

PR Newswire 07 Jan 2019

XmAb13676 is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3) in a Phase 1 clinical trial for the treatment of B-cell malignancies ... CD20 is highly expressed on B-cell tumors, including in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL)....

Edit

Timothy Paul Johnson

Index-Journal 07 Jan 2019

Timothy Paul Johnson ... .......

Edit

Cousins, offense off track again as Vikings fall to Bears

Aberdeen News 31 Dec 2018

MINNEAPOLIS (AP) — After Kirk Cousins underthrew Adam Thielen, one of 10 failures to move the chains out of 11 third-down plays for Minnesota, two of the team's best players engaged in an animated and heated discussion on the sideline .......

Edit

Spurs make season-high 19 3-pointers, rout Wolves 124-98

The Galveston Daily News 22 Dec 2018

SAN ANTONIO (AP) — There truly is no place like home lately for the San Antonio Spurs, especially after some struggles at the start of the month. Bryn Forbes scored 22 points and the Spurs set season highs with 19 3-pointers and 36 assists in a 124-98 win over the Minnesota Timberwolves on Friday night ... The Spurs' run of blowout losses began Nov ... 22....

Edit

Bio-Thera Solutions Initiates Phase I Clinical Trial for BAT4306F, an ADCC-enhanced CD20 monoclonal antibody

Harrison Daily 07 Dec 2018

GUANGZHOU, China--(BUSINESS WIRE)--Dec 7, 2018--Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that patient dosing has begun in a Phase I clinical study of BAT4306F in relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma patients. BAT4306F is an ADCC-enhanced CD20 monoclonal antibody that ... ....